Juan Luis Becerra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Juan Luis Becerra has a total of 280 co-authors. Here are the top co-authors by number of shared publications:
- Laia Grau-López
Department of Neurosciences, Hospital Germans Trias i Pujol, C/ Canyet s/n, 08916 Badalona, Spain
5 shared publications - Mar Carreño
Biomedical Research Institute August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Barcelona, Spain
5 shared publications Albert Molins
Department of Neurology, Hospital Trueta, Girona, Spain
3 shared publicationsMarta Jiménez
Epilepsy Unit, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
3 shared publicationsA. Molins
Neurology Department, Hospital Josep Trueta, Girona, Spain
2 shared publicationsAlejandra Fumanal
Department of Neurosciences, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona C/Canyet s/n, 08916 Badalona, Spain
2 shared publications
Latest Publications
- 4 February 2022
- Published by BMJ in Journal of Medical Genetics
- Vol. 59 (10) , 1017-1023
Neurofibromatosis type 1 families with first-degree relatives harbouring distinct NF1 pathogenic variants. Genetic counselling and familial diagnosis: what should be offered?
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder caused by pathogenic variants in NF1. Recently, NF1 testing has been included as a clinical criterion for NF1 diagnosis. Additionally, preconception genetic counselling in patients with NF1 focuses on a 50% risk of transmitting the familial variant as the risk of having a sporadic NF1 is considered the same as the general population. Methods: 829 individuals, 583 NF1 sporadic cases and 246 patients with NF1 with documented family history, underwent genetic testing for NF1. Genotyping and segregation analysis of NF1 familial variants was determined by microsatellite analysis and NF1 sequencing. Results: The mutational analysis of NF1 in 154 families with two or more affected cases studied showed the co-occurrence of two different NF1 germline pathogenic variants in four families. The estimated mutation rate in those families was 3.89×10–3, 20 times higher than the NF1 mutation rate (~2×10−4) (p=0.0008). Furthermore, the co-occurrence of two different NF1 germline pathogenic variants in these families was 1:39, 60 times the frequency of sporadic NF1 (1:2500) (p=0.003). In all cases, the de novo NF1 pathogenic variant was present in a descendant of an affected male. In two cases, variants were detected in the inherited paternal wild-type allele. Conclusions: Our results, together with previous cases reported, suggest that the offspring of male patients with NF1 could have an increased risk of experiencing de novo NF1 pathogenic variants. This observation, if confirmed in additional cohorts, could have relevant implications for NF1 genetic counselling, family planning and NF1 genetic testing.
- 4 February 2022
- Published by BMJ in Journal of Medical Genetics
- Vol. 59 (10) , 1017-1023
Neurofibromatosis type 1 families with first-degree relatives harbouring distinct NF1 pathogenic variants. Genetic counselling and familial diagnosis: what should be offered?
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder caused by pathogenic variants in NF1. Recently, NF1 testing has been included as a clinical criterion for NF1 diagnosis. Additionally, preconception genetic counselling in patients with NF1 focuses on a 50% risk of transmitting the familial variant as the risk of having a sporadic NF1 is considered the same as the general population. Methods: 829 individuals, 583 NF1 sporadic cases and 246 patients with NF1 with documented family history, underwent genetic testing for NF1. Genotyping and segregation analysis of NF1 familial variants was determined by microsatellite analysis and NF1 sequencing. Results: The mutational analysis of NF1 in 154 families with two or more affected cases studied showed the co-occurrence of two different NF1 germline pathogenic variants in four families. The estimated mutation rate in those families was 3.89×10–3, 20 times higher than the NF1 mutation rate (~2×10−4) (p=0.0008). Furthermore, the co-occurrence of two different NF1 germline pathogenic variants in these families was 1:39, 60 times the frequency of sporadic NF1 (1:2500) (p=0.003). In all cases, the de novo NF1 pathogenic variant was present in a descendant of an affected male. In two cases, variants were detected in the inherited paternal wild-type allele. Conclusions: Our results, together with previous cases reported, suggest that the offspring of male patients with NF1 could have an increased risk of experiencing de novo NF1 pathogenic variants. This observation, if confirmed in additional cohorts, could have relevant implications for NF1 genetic counselling, family planning and NF1 genetic testing.
- 1 July 2018
- Published by Elsevier in Epilepsy & Behavior
- Vol. 84, 93-98
Intravenous lacosamide (LCM) in status epilepticus (SE): Weight-adjusted dose and efficacy
- 1 July 2018
- Published by Elsevier in Epilepsy & Behavior
- Vol. 84, 93-98
Intravenous lacosamide (LCM) in status epilepticus (SE): Weight-adjusted dose and efficacy
- Top Cited Papers
- 1 June 2018
- Published by Elsevier in The Lancet Neurology
- Vol. 17 (6) , 530-538
Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry
- 1 June 2018
- Published by Elsevier in The Lancet Neurology
- Vol. 17 (6) , 530-538
Top Cited PapersComparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry
- 1 March 2018
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 154 (3) , 341-346
Early Genetic Diagnosis of Neurofibromatosis Type 2 From Skin Plaque Plexiform Schwannomas in Childhood
Importance Neurofibromatosis type 2 (NF2) is a devastating genetic condition characterized by the development of multiple tumors of the nervous system. An early diagnosis of individuals with NF2 would facilitate treatment and reduction of disease impact because most severe effects of the disease do not usually develop before adolescence. Little attention has traditionally been paid to dermatological signs in NF2. However, skin plaques are commonly seen in patients with NF2, normally appearing either at birth or early childhood, providing an opportunity for early NF2 detection and testing. Objective To determine the clinical utility of skin plaque identification and characterization in children for reaching an early diagnosis of patients with NF2 and to evaluate their molecular pathogenesis and their use in the genetic diagnostics of NF2. Design, Setting, and Participants Diagnostic test study by the histological and genetic characterization of skin plaques from patients with NF2. Patients were 7 individuals with NF2 or clinical suspicion of NF2 treated at the Spanish Reference Center on Phakomatoses. Main Outcomes and Measures Histological evaluation of all skin plaques was performed. Fresh skin plaques were cultured to obtain Schwann cells and theNF2gene was genetically analyzed. For all 7 patients, NF2 clinical history was reviewed. Results In all 7 patients (4 male and 3 female), all skin plaques analyzed were histologically characterized as plexiform schwannomas. Genetic analysis of primary Schwann cell cultures derived from them allowed the identification of a constitutional and a somaticNF2mutation. Genetic testing allowed the early diagnosis of NF2 in a child only exhibiting the presence of skin plaques. Most of the patients with NF2 analyzed had an early presentation of skin plaques and a severe NF2 phenotype. Conclusions and Relevance This work emphasizes the clinical utility of a careful dermatological inspection and the correct identification of skin plaques in children for an early diagnosis of NF2. We show for the first time that Schwann cells derived from skin plaque plexiform schwannomas bear the double inactivation of theNF2gene and thus constitute an excellent source of tissue for genetic testing, especially in the context of mosaicism.
- 1 March 2018
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 154 (3) , 341-346
Early Genetic Diagnosis of Neurofibromatosis Type 2 From Skin Plaque Plexiform Schwannomas in Childhood
Importance Neurofibromatosis type 2 (NF2) is a devastating genetic condition characterized by the development of multiple tumors of the nervous system. An early diagnosis of individuals with NF2 would facilitate treatment and reduction of disease impact because most severe effects of the disease do not usually develop before adolescence. Little attention has traditionally been paid to dermatological signs in NF2. However, skin plaques are commonly seen in patients with NF2, normally appearing either at birth or early childhood, providing an opportunity for early NF2 detection and testing. Objective To determine the clinical utility of skin plaque identification and characterization in children for reaching an early diagnosis of patients with NF2 and to evaluate their molecular pathogenesis and their use in the genetic diagnostics of NF2. Design, Setting, and Participants Diagnostic test study by the histological and genetic characterization of skin plaques from patients with NF2. Patients were 7 individuals with NF2 or clinical suspicion of NF2 treated at the Spanish Reference Center on Phakomatoses. Main Outcomes and Measures Histological evaluation of all skin plaques was performed. Fresh skin plaques were cultured to obtain Schwann cells and theNF2gene was genetically analyzed. For all 7 patients, NF2 clinical history was reviewed. Results In all 7 patients (4 male and 3 female), all skin plaques analyzed were histologically characterized as plexiform schwannomas. Genetic analysis of primary Schwann cell cultures derived from them allowed the identification of a constitutional and a somaticNF2mutation. Genetic testing allowed the early diagnosis of NF2 in a child only exhibiting the presence of skin plaques. Most of the patients with NF2 analyzed had an early presentation of skin plaques and a severe NF2 phenotype. Conclusions and Relevance This work emphasizes the clinical utility of a careful dermatological inspection and the correct identification of skin plaques in children for an early diagnosis of NF2. We show for the first time that Schwann cells derived from skin plaque plexiform schwannomas bear the double inactivation of theNF2gene and thus constitute an excellent source of tissue for genetic testing, especially in the context of mosaicism.
- 1 February 2018
- Published by Elsevier in Epilepsy & Behavior
- Vol. 79, 87-92
Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: A prospective multicenter study
- 1 February 2018
- Published by Elsevier in Epilepsy & Behavior
- Vol. 79, 87-92
Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: A prospective multicenter study
- 24 November 2017
- Published by Wiley in Journal of Sleep Research
- Vol. 27 (5) , e12640
The prevalence of narcolepsy in Catalunya (Spain)
Summary: Previous studies have estimated an overall prevalence for narcolepsy between 15 and 70 cases per 100 000 inhabitants. We aimed to estimate the prevalence of narcolepsy in Catalunya (Catalonia), a north‐east region of Spain (7 424 754 inhabitants), on 31 December 2014 by identifying all living subjects diagnosed with narcolepsy. First, we identified patients diagnosed by one of the 13 sleep, paediatric or neurological departments that perform tests regularly to diagnose narcolepsy. In a second phase, we searched for additional patients with narcolepsy in a clinical database of the primary health‐care system. Clinical files were reviewed and narcolepsy diagnosis validated according to the Brighton Collaboration case definitions. Three hundred and twenty‐five patients had a validated diagnosis of narcolepsy in the specialized centres (mean age: 44.6 years, range: 6–89; male: 60.3%; 85% with narcolepsy type 1), including 17.8% cases in Brighton, definition level 1, 62.5% in level 2, 15.4% in level 3 and 4.3% in level 4a. The overall prevalence for narcolepsy was 4.4; 3.7 for narcolepsy type 1 and 0.7 cases per 100 000 inhabitants for narcolepsy type 2. Fifty‐six additional narcoleptic patients were identified in the primary health‐care system, increasing the overall prevalence to 5.2 cases per 100 000 inhabitants. Prevalence rates for narcolepsy type 1 increased from childhood to adulthood, but in subjects aged more than 50 years there was a substantial drop in prevalence rates, suggesting the presence of a significant pool of undiagnosed cases in this population. Narcolepsy can be considered a rare neurological disorder in Catalunya.
- 24 November 2017
- Published by Wiley in Journal of Sleep Research
- Vol. 27 (5) , e12640
The prevalence of narcolepsy in Catalunya (Spain)
Summary: Previous studies have estimated an overall prevalence for narcolepsy between 15 and 70 cases per 100 000 inhabitants. We aimed to estimate the prevalence of narcolepsy in Catalunya (Catalonia), a north‐east region of Spain (7 424 754 inhabitants), on 31 December 2014 by identifying all living subjects diagnosed with narcolepsy. First, we identified patients diagnosed by one of the 13 sleep, paediatric or neurological departments that perform tests regularly to diagnose narcolepsy. In a second phase, we searched for additional patients with narcolepsy in a clinical database of the primary health‐care system. Clinical files were reviewed and narcolepsy diagnosis validated according to the Brighton Collaboration case definitions. Three hundred and twenty‐five patients had a validated diagnosis of narcolepsy in the specialized centres (mean age: 44.6 years, range: 6–89; male: 60.3%; 85% with narcolepsy type 1), including 17.8% cases in Brighton, definition level 1, 62.5% in level 2, 15.4% in level 3 and 4.3% in level 4a. The overall prevalence for narcolepsy was 4.4; 3.7 for narcolepsy type 1 and 0.7 cases per 100 000 inhabitants for narcolepsy type 2. Fifty‐six additional narcoleptic patients were identified in the primary health‐care system, increasing the overall prevalence to 5.2 cases per 100 000 inhabitants. Prevalence rates for narcolepsy type 1 increased from childhood to adulthood, but in subjects aged more than 50 years there was a substantial drop in prevalence rates, suggesting the presence of a significant pool of undiagnosed cases in this population. Narcolepsy can be considered a rare neurological disorder in Catalunya.
- 7 September 2017
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 43 (7) , 636-640
Incidental neuronal intermediate filament inclusion pathology: unexpected biopsy findings in a 37‐year‐old woman with epilepsy
- 7 September 2017
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 43 (7) , 636-640
Incidental neuronal intermediate filament inclusion pathology: unexpected biopsy findings in a 37‐year‐old woman with epilepsy
- 1 September 2017
- Published by Wolters Kluwer Health in Journal Of Clinical Neurophysiology
- Vol. 34 (5) , 434-437
Diagnostic Yield of Routine Electroencephalography With Concurrent Video Recording in Detecting Interictal Epileptiform Discharges in Relation to Reasons for Request: A Prospective Study of 1,080 Video-Electroencephalograms
The aim of this study was to prospectively analyze the sensitivity and specificity of routine electroencephalography with concurrent video recording (vEEG) in relation to the reasons for requesting the test and to investigate when routine vEEG should be requested. We prospectively analyzed 1,080 consecutive vEEGs performed between April 2015 and April 2016. The requests for vEEG were classified as requests with a low suspicion of epilepsy (syncope, confusion or delirium, suspicion of psychogenic nonepileptic seizures, and paroxysmal focal neurological deficit) or requests with a high suspicion of epilepsy (first clinical seizure, suspected status epilepticus, follow-up study of a patient with epilepsy, and acute symptomatic seizures). Predominant vEEG findings (ictal and interictal epileptiform activities, diffuse, or focal slowing and triphasic waves) were analyzed, and sensitivity and specificity [ZERO WIDTH SPACE][ZERO WIDTH SPACE]values calculated. The most common indication for vEEG was a follow-up study of patients with epilepsy (38%), followed by first clinical seizure (19.3%) and suspected status epilepticus (11%). The respective specificity and sensitivity values were 93% and 58% for 235 vEEGs performed in children/adolescents (≤18 years), 95% and 40% for 533 vEEGs performed in adults (>18 ≤ 65 years), and 93% and 39% for 312 vEEGs performed in older adults (>65 years). Twenty-four patients with false-positive paroxysms had a clinical diagnosis of confusional state or paroxysmal focal neurological deficit. Neurologists and neuropediatricians with experience in managing epilepsy had higher specificity values than general neurologists or physicians (P = 0.012). In our series, vEEG abnormalities were mainly observed in patients with clinical findings highly suggestive of epilepsy. In confusional states, and paroxysmal focal neurological deficit vEEG could be indicated.
- 1 September 2017
- Published by Wolters Kluwer Health in Journal Of Clinical Neurophysiology
- Vol. 34 (5) , 434-437
Diagnostic Yield of Routine Electroencephalography With Concurrent Video Recording in Detecting Interictal Epileptiform Discharges in Relation to Reasons for Request: A Prospective Study of 1,080 Video-Electroencephalograms
The aim of this study was to prospectively analyze the sensitivity and specificity of routine electroencephalography with concurrent video recording (vEEG) in relation to the reasons for requesting the test and to investigate when routine vEEG should be requested. We prospectively analyzed 1,080 consecutive vEEGs performed between April 2015 and April 2016. The requests for vEEG were classified as requests with a low suspicion of epilepsy (syncope, confusion or delirium, suspicion of psychogenic nonepileptic seizures, and paroxysmal focal neurological deficit) or requests with a high suspicion of epilepsy (first clinical seizure, suspected status epilepticus, follow-up study of a patient with epilepsy, and acute symptomatic seizures). Predominant vEEG findings (ictal and interictal epileptiform activities, diffuse, or focal slowing and triphasic waves) were analyzed, and sensitivity and specificity [ZERO WIDTH SPACE][ZERO WIDTH SPACE]values calculated. The most common indication for vEEG was a follow-up study of patients with epilepsy (38%), followed by first clinical seizure (19.3%) and suspected status epilepticus (11%). The respective specificity and sensitivity values were 93% and 58% for 235 vEEGs performed in children/adolescents (≤18 years), 95% and 40% for 533 vEEGs performed in adults (>18 ≤ 65 years), and 93% and 39% for 312 vEEGs performed in older adults (>65 years). Twenty-four patients with false-positive paroxysms had a clinical diagnosis of confusional state or paroxysmal focal neurological deficit. Neurologists and neuropediatricians with experience in managing epilepsy had higher specificity values than general neurologists or physicians (P = 0.012). In our series, vEEG abnormalities were mainly observed in patients with clinical findings highly suggestive of epilepsy. In confusional states, and paroxysmal focal neurological deficit vEEG could be indicated.